Introduction
Cases of nonesmall-cell lung cancer (NSCLC) harboring a somatic mutation in EGFR respond dramatically to initial EGFR tyrosine kinase inhibitors (TKIs), although acquired resistance will develop in w1 year. [1] [2] [3] A variety of acquired resistance mechanisms have been reported, including secondary T790M mutation, bypass or alternative pathway activation, and histologic and phenotypic transformation. 4 Osimertinib, one of the third-generation EGFR TKIs, is selective for sensitizing mutations and the T790M resistance mutation 5 and was approved for the treatment of advanced NSCLC in which T790M-mediated drug resistance has developed. Strategies for other resistance mechanisms are now under development. We report a rare case of EGFR-mutated lung adenocarcinoma that showed histologic transformation to squamous cell carcinoma (SCC) concurrently with a secondary T790M mutation and responded to osimertinib.
Case Report
Left upper lobe adenocarcinoma (T2aN0M0, stage IB) was diagnosed in a 68-year-old man, a 50 pack-year former smoker, during a medical examination. We performed radical surgery with lobectomy and lymph node dissection, followed by adjuvant chemotherapy with 250 mg of UFT (uracil, tegafur) bid for 2 years. During follow-up examinations, a solitary brain metastasis was found 4 years after the operation. The patient underwent stereotactic radiosurgery for the brain metastasis and was monitored without the use of systemic therapy. However, his disease subsequently relapsed, with detection of a right adrenal lesion 1 year after stereotactic radiosurgery. Molecular analysis of the resected lung demonstrated an EGFR point mutation (L858R) in exon 21. The
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improved. Despite the radiologic and clinical response, we had to discontinue treatment with osimertinib owing to an adverse effect (grade 3 interstitial lung disease) 3 months after drug administration. Discontinuation of osimertinib and introduction of systemic steroid therapy (prednisolone 0.5 mg/kg/day) resulted in remission of interstitial lung disease. However, the known adrenal lesion enlarged and invaded into the stomach, resulting in severe bleeding. The patient could not receive additional chemotherapy and died of disease 3 months after discontinuation of osimertinib.
Discussion
The most common acquired resistance mechanism after initial EGFR TKI treatment is the secondary T790M mutation of EGFR (> 50%-60% of patient cases), and histologic transformation to small-cell lung cancer (SCLC) has been reported in 3% to 14% of patients with acquired resistance to initial EGFR TKI treatment. 6, 7 However, transformation to SCC in EGFR-mutated lung adenocarcinoma is a very rare mechanism of acquired resistance to EGFR TKI. In total, 10 cases of EGFR-mutated NSCLC that had transformed to SCC have been identified to date from PubMed (Table 1) . [8] [9] [10] [11] [12] [13] [14] As shown in Table 1 , the age of all 11 patients, including our patient, ranged from 43 to 79 years (median age, 64 years). Of all 11 patients, 6 (54.5%) were never smokers and 3 (27.3%) were former smokers. All 11 patients had EGFR mutations: 7 patients had an exon 21 point mutation (L858R) and 4 patients had an exon 19 deletion. The patient characteristics were not different from those of patients with treatment-naive EGFR-mutated NSCLC. [1] [2] [3] All these patients received a first-generation EGFR TKI (gefitinib or erlotinib) as initial EGFR TKI treatment. Of the 8 patients available for evaluation of the response to initial EGFR TKI therapy, 7 (87.5%) achieved a PR and 1 had stable disease. The interval to treatment failure ranged from 5 months to 2 years (median, 9.5 months). Unsampled combined components (adenosquamous carcinoma) might have been selected under the treatment pressure of EGFR TKIs in these cases. However, in 3 patients, including our patient, adenocarcinoma was diagnosed by evaluating surgically resected samples. In our patient, no squamous cell carcinoma lesion was present in the resected lung. In addition, the duration of response to EGFR TKI therapy in the remaining patients, diagnosed by small biopsy or cytology, was 5 to 15 months (median, 9 months), longer than that of the cases of non-adenocarcinoma NSCLC with an activating EGFR mutation (median, 3.1 months). 15 These results suggest that these cases, including our case (Table 1) , actually developed histologic transformation from adenocarcinoma to SCC through the process of developing acquired resistance. At present, among the acquired resistance mechanisms to EGFR TKIs, the cases with a secondary EGFR T790M mutation and those with SCLC transformation can receive treatment according to the resistance mechanisms. T790M-specific third-generation EGFR TKIs apparently prolong progression-free survival compared with standard platinum-based chemotherapy in patients with EGFR T790M mutations. 5 Sequist et al 7 reported that patients with EGFR-mutated NSCLC that had transformed to SCLC responded to chemotherapy regimens used for SCLC. Because of the rarity of EGFR-mutated NSCLC developing SCC transformation, no specific treatment for these patients has been established. Pemetrexed-based chemotherapy is inferior to that of Table 1 
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other third-generation cytotoxic agents (eg, gemcitabine or docetaxel) for patients with SCC compared with those with nonsquamous NSCLC. 16 Combined pemetrexed with carboplatin treatment did not result in a response in our patient. Thus, pemetrexed treatment might be less effective for SCC that has transformed from adenocarcinoma, similar to original SCC. SCC transformation, concurrent with T790M mutation, has been reported in 3 cases to date 12, 13 ; however, the efficacy and safety of T790M-specific EGFR TKIs are unclear in this setting. Haratani et al 13 reported a case that was successfully treated with rociletinib, one of the third-generation EGFR-TKIs, in the same setting. To the best of our knowledge, our is the first case of EGFR-mutated adenocarcinoma transforming to SCC concurrent with a secondary T790M mutation that was treated with and responded to osimertinib, which is the only third-generation EGFR TKI available in clinical practice. T790M-specific third-generation EGFR TKIs, including osimertinib, could be a promising strategy for EGFR T790M mutation-positive NSCLC, regardless of the histologic findings. However, further studies are necessary to establish the optimal treatment for patients with EGFRmutated NSCLC who have developed histologic transformation to SCC with a secondary T790M mutation.
Conclusions
We report a rare case of EGFR-mutated lung adenocarcinoma that transformed to SCC concurrent with secondary T790M mutation. Osimertinib could be a promising strategy for patients with EGFR-mutated NSCLC with SCC transformation and a secondary T790M mutation and should be evaluated in further studies.
